不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血细胞来源移植 40 年
英文原题：Blood cell-derived transplants at 40.
查看英文原题
Blood cell-derived transplants at 40.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2026年2月是首次发表高剂量化疗后输注自体血液来源而非骨髓来源移植物后骨髓功能快速恢复的40周年。受者是一名晚期Burkitt淋巴瘤男性，目前处于缓解状态并存活。在随后的40年中，血液来源祖细胞移植已成为自体移植和异体移植中最常见的移植物。与骨髓来源移植物相比，血液细胞来源移植物后的快速造血恢复与更少的短期并发症和许多情况下更好的结局相关，但在异体移植后可能与更多的移植物抗宿主病（GvHD）相关。使用血液来源移植物还降低了成本，促进了基于细胞的免疫治疗的发展，以及用于基因和嵌合抗原受体（CAR）-T细胞治疗的血液来源细胞的体外操作。
展开英文摘要原文
February, 2026 is the 40th anniversary of the 1st publication of rapid recovery of bone marrow function after high-dose chemotherapy and infusion of an autologous blood- rather than a bone-marrow-derived graft. The recipient, a man with advanced Burkitt lymphoma, is in remission and alive. In the next 40 years transplants of blood-derived progenitor cells have become the most common graft for auto- and allotransplants.
The rapid hematopoietic recovery after blood cell-derived grafts is associated with fewer short-term complications and better outcomes in many settings compared with bone marrow-derived grafts but may be associated with more graft-versus-host disease (GvHD) after allotransplants. Using blood-derived grafts also reduced costs, enabled the development of cell-based immune therapy and in vitro manipulation of blood-derived cells for gene and chimeric antigen receptor (CAR)-T-cell therapies.
论文信息
- 作者
- Ho AD、Dreger P、Juttner C、Gale RP
- 单位
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany. anthony_dick.ho@urz.uni-heidelberg.de.Germany
- 文献类型
- 综述
- 期刊
- Bone marrow transplantation2026 Jun
- 原文标识
- PubMed 41981080 · DOI 10.1038/s41409-026-02865-6
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →